drugset / Trial / NCT02610400

Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia

NCT02610400

RandomizedFactorialOpen-labelTreatment

Summary

This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus reactive case detection (RACD), and 2) reactive IRS (indoor residual spraying) versus control on the incidence of malaria in Namibia.

Timeline

Start
2016-02
Primary completion
2017-12
Completion
2017-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether Small molecule 20 mg
Subject Artemether Small molecule 40 mg
Subject Artemether Small molecule 60 mg
Subject Artemether Small molecule 80 mg
Subject lumefantrine Small molecule 120 mg
Subject lumefantrine Small molecule 240 mg
Subject lumefantrine Small molecule 360 mg
Subject lumefantrine Small molecule 480 mg
Subject pirimiphos-methyl Small molecule Other

Indications